Table 5.

Overview of polymorphisms in toll-like receptor genes encoding receptors and association with cervical neoplasia risk.

Gene	Polymorphisma	Cohort	Cases (n)	Population	Distribution	Risk (OR, 95% CI); PAFb,c,d	Reference
TLR2	c.+613T>C (rs3804100)	CIN III Cervical cancer	470	Costa Rican	Genotypes	TC: 0.61 (0.39–0.95)  CC: 0.56 (0.09–3.50) TC/CC: 0.61 (0.40–0.93)	[36]
TLR4	c.+936C>T (rs4986791)	Cervical cancer	150	North Indian	Genotypes	Overall CT: 1.50 (0.72–2.92) TT: 2.20 (0.20–24.76) Stage II CT: 2.50 (1.03–6.12); 12.5%  TT: - Stage III CT: 1.30 (0.54–2.97) TT: 4.20 (0.37–47.64)	[37]
TLR9	c.+2848G>A (rs382140)	Cervical cancer	120	Chinese Han	Alleles	A: 7.001 (2.422–20.23); 10.7%	[38]
					Genotypes	GA: 6.929 (1.534–33.30); 10.0%  AA: 7.918 (1.797–64.52); 5.9%  GA/AA: 7.259 (2.104–25.05); 15.8%
			426	Polish	Genotypes	GA: 1.443 (1.019–2.043); 16.6%  AA: 1.237 (1.016–1.507); 5.0%  GA/AA: 1.345 (0.976–1.855)	[39]
TLR9	c.-1486T>C (rs187084)	Cervical cancer	712	Chinese	Genotypes	TC: 1.28 (1.01–1.62)   TC/CC: 1.24 (1.01–1.53)	[40]
			426	Polish	Genotypes	TC: 1.371 (1.021–1.842); 13.0%  CC: 1.300 (1.016–1.507); 4.4%  TC/CC: 1.448 (1.099–1.908); 20.7%	[39]

n: number of cases; OR: odds ratio; 95% CI: 95% confidence interval; CIN: cervical intraepithelial neoplasia; PAF: population attributable fraction.

^aNucleotide variation and dbSNP reference number.

^bOR relative to major allele or major allele homozygotes.

^cPAF listed if OR > 1.00.

^dSignificant associations listed in bold.